"In May 2003, Easton led a $55.3 million financing for Acorda Therapeutics,
one of the top three private biotechnology financings to date in 2003. Easton's ability to lead
such a significant round, particularly in a challenging financial environment, is a testament to
its capabilities and excellence. Acorda's management and Board were thoroughly impressed by the
acumen and performance of the people at Easton. They comprise a rare mix of expertise in finance,
life sciences, business development and value creation, together with meticulous attention to detail
and passionate commitment. We are especially pleased that John Friedman has joined our Board of
Directors, where we expect his insights to contribute substantially to Acorda's future successes."
Ron Cohen
Founder, President, and CEO, Acorda Therapeutics
Gentis, Inc.
Gentis develops synthetic products that represent
fundamental improvements for treating degenerated intervertebral discs
of the spine and other musculoskeletal lesions. The Company's work
since 2000 has led to far-reaching patent applications, especially with
respect to its first spinal product. In the longer-term Gentis' broad
technology platform also creates a product pipeline that will enable it
to build an all-inclusive, world class Orthobiologics Company. Easton
co-led an investment in Gentis in June 2007. Other investors in the
Company include Pappas Ventures, Ivy Capital Partners and Matignon
Technologies.